勇敢之心生物 BRVE

J. Paul Rickey has served as our Chief Financial Officer since November 2025. Most recently, Mr. Rickey served as the SVP, Chief Financial Officer at Alpine Immune Sciences, Inc. (previously Nasdaq: ALPN) from April 2017 through its acquisition by Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX) in June 2024, including serving as its Treasurer from December 2018 to June 2024 and Secretary from March 2019 to June 2024. Prior to that, Mr. Rickey served as the Chief Financial Officer at Sound Pharmaceuticals, Inc. from March 2016 to March 2017. Prior to that, Mr. Rickey served as the Vice President, Treasurer, Secretary, Principal Financial Officer, and Principal Accounting Officer at Immune Design Corp. (previously, Nasdaq: IMDZ) from July 2009 to June 2015. Prior to that, Mr. Rickey held finance and operating roles at public and private life science and technology companies, including Northstar Neuroscience, Inc. (previously, Nasdaq: NSTR) from July 2006 to June 2009, and Mobliss Inc. from August 2004 to July 2006. He began his career at Ernst & Young from 2001 to 2004. Mr. Rickey holds a B.A. and Master of Professional Accounting from the University of Washington and is a Certified Public Accountant (inactive).

Christopher Viehbacher has served as a member of our board of directors and Chairman of the board of directors since November 2025. Currently, Mr. Viehbacher is the President, Chief Executive Officer and a member of the board of directors of Biogen Inc. (Nasdaq: BIIB) since November 2022. Previously, Mr. Viehbacher was the co-founder and managing partner at Gurnet Point Capital LLC, a Cambridge-based healthcare investment fund from July 2015 to November 2022. Prior to that he was the Global Chief Executive Officer at Sanofi S.A. (Nasdaq: SNY) from December 2008 to October 2014 and started his career at GlaxoSmithKline plc (NYSE: GSK), where he held various roles between 1984 to 2008. Mr. Viehbacher previously served as the chair of the board of directors at PureTech Health plc (Nasdaq: PRTC) between March 2015 to May 2023 and has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology. He has received a number of awards including the Legion d'Honneur from France. He is Trustee of Northeastern University, a member of the Board of Fellows of the Stanford Medical School and a member of the MIT President's CEO Advisory Board. Mr. Viehbacher holds a B. Comm from Queen's University, Kingston, Canada.

Travis Murdoch, M.D., has served as our Chief Executive Officer since July 2025, as our President since October 2025, and as a member of our board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI-Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co-Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co-Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to

Marc Evanchik, M.S., has served as our Chief Scientific Officer since January 2026 and was previously our SVP, Pharmacology and Translational Medicine from October 2025 to January 2026. Most recently, Mr. Evanchik was VP of Discovery and Translational Pharmacology at Edgewise Therapeutics, Inc. (Nasdaq: EWTX) from December 2020 to February 2025, where he led cardiovascular research. Prior to that, Mr. Evanchik served as the Senior Director DMPK at Assembly Biosciences, Inc. (Nasdaq: ASMB) from January 2019 to December 2020. Previously, he held various roles at MyoKardia, Inc. (previously, Nasdaq: MYOK) from October 2012 to September 2018 where he played a key role in establishing pharmacology capabilities. From July 2008 to October 2009, Mr. Evanchik was at ChemoCentryx, Inc. (previously, Nasdaq: CCXI) and from October 2009 to October 2012, he was at 3-V Biosciences, Inc. (currently, Sagimet Biosciences, Inc. (Nasdaq: SGMT)). Mr. Evanchik started his career as an Associate Scientist at Sunesis Pharmaceutics Inc. (currently, Viracta Therapeutics, Inc. (Nasdaq: VIRX)) from 2002 to 2008. Mr. Evanchik is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. He holds a B.S. in Chemistry from the University of California, Santa Cruz, and an M.S. in Chemistry from the University of California, Davis.

Jasper Bos, Ph.D., has served as a member of our board of directors since September 2025. Dr. Bos is currently a General Partner at Forbion Growth, a global venture capital firm investing in biotech companies, since May 2021 and previously served as the Chief Executive Officer of Forbion European Acquisitions Corporation (previously, Nasdaq: FRBN) from December 2021 to November 2023. Before joining Forbion's Naarden-based headquarters, Dr. Bos was Senior Vice President and Managing Director at M Ventures from June 2016 to May 2021, leading the venture capital arm of pharmaceutical company Merck & Co., Inc. (NYSE: MRK). He served in various roles at Merck from May 2009 to May 2016, including as Country Speaker Merck Netherlands where he assumed responsibility and liaised between all Merck activities in the Netherlands. Dr. Bos currently serves on the board of directors of several private companies. He has previously served on the board of directors of enGene Holdings, Inc. (Nasdaq: ENGN) from November 2023 to July 2025, and has served on multiple boards of directors of private biotech companies. He has experience in several operational roles in portfolio companies and played a key role in the creation of multiple successful spin-out companies out of Merck, such as Prexton Therapeutics (sold to Lundbeck) and Calypso biotech (sold to Novartis). Dr. Bos holds a Ph.D. in Pharmacy from the University of Groningen, the Netherlands.

Tim Lohoff, Ph.D., has served as a member of our board of directors since September 2025. Currently he is a Principal at Forbion Ventures, a global venture capital firm investing in biotech companies, where he has held various roles since February 2022. He also serves as a member of the board of directors at several private biotechnology companies. Prior to Forbion, he began his career as a Life Sciences Specialist at L.E.K. Consulting LLC from August 2021 to February 2022. Dr. Lohoff has received his Ph.D. from University of Cambridge in 2021, his M.Sc from TU Dresden and B.Sc from University of Bielefeld.

Emil deGoma, M.D., has served as our Chief Medical Officer since March 2026. Most recently, Dr. deGoma served as Senior Vice President of Medical Research at Tourmaline Bio, Inc. (formerly, Nasdaq: TRML), from October 2023 to December 2025, including through the completion of its acquisition by Novartis AG in October 2025. Previously, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC from January 2023 to October 2023. Before that, he served as Senior Vice President of Clinical Development & Data Science at ChemoCentryx, Inc. (formerly, Nasdaq: CCXI) from November 2021 to October 2022 and, following ChemoCentryx's acquisition, as Vice President of Clinical Development at Amgen, Inc. (Nasdaq: AMGN) from October 2022 to December 2022. Earlier, he served as Vice President of Clinical Development at Exicure, Inc. (Nasdaq: XCUR) from May 2020 to November 2021. From August 2019 to April 2020, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC, and from March 2016 to July 2019, he served in positions of increasing responsibility at Akebia Therapeutics, Inc. (Nasdaq: AKBA), most recently as Vice President of Clinical Development. Earlier in his career, Dr. deGoma served as an Assistant Professor and Medical Director at the University of Pennsylvania. Dr. deGoma received an A.B. in Biochemical Sciences from Harvard College and an M.D. from Harvard Medical School and completed his internal medicine residency and cardiovascular medicine fellowship at Stanford University. Dr. deGoma is a board-certified cardiologist and is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association.

Tyler Chavez, Ph.D., has served as our Chief Business Officer since June 2026. Most recently, Dr. Chavez was the Head of Corporate Development at Ouro Medicines LLC from August 2025 to June 2026, when it was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT). Prior to that, he served as Head of Corporate Development and Alliance Management at Human Immunology Biosciences, Inc. (f/k/a HI-Bio, Inc.) from July 2022 to August 2025, including following its acquisition by Biogen Inc. (Nasdaq: BIIB) in July 2024. Previously, he held various roles at BeiGene Medicines Ltd. (Nasdaq: ONC) from December 2019 to July 2022. Dr. Chavez held prior roles at AppliedVR from November 2018 to December 2019, Spark Therapeutics, Inc. (previously, Nasdaq: ONCE) from May 2017 to November 2018 and at Johns Hopkins Technology Ventures from October 2014 to April 2017, where he started his career. Tyler holds a B.S. in Chemistry from Sonoma State University, an M.S. in Organic Chemistry from Johns Hopkins University and a Ph.D. in Chemistry from Johns Hopkins University.

Vineeta Agarwala, M.D., Ph.D., shall join as a member of our board of directors immediately following the closing of this offering. Dr. Agarwala has served as a General Partner at Andreessen Horowitz since January 2020, where she focuses on investments in biotechnology and health technology companies and serves on the boards of directors of several private portfolio companies. Prior to joining Andreessen Horowitz, Dr. Agarwala served as a Venture Partner at Google Ventures, from March 2015 to December 2019, where she supported early-stage investments across biotechnology and digital health. From August 2016 to June 2018, Dr. Agarwala served as Director of Product Management at Flatiron Health, Inc, where she helped build an oncology data platform and led a partnership to integrate real-world clinical and genomic datasets. Dr. Agarwala has served on the board of directors of Tenet Healthcare Corporation (NYSE: THC) since January 2024. She has served as a member of the board of directors of the National Venture Capital Association (NVCA) since April 2021 and also served as Chair of the NVCA board of directors for the 2025-2026 term. Dr. Agarwala is an Adjunct Clinical Assistant Professor at Stanford University School of Medicine, where she practices in the Division of Primary Care and Population Health since 2020. Dr. Agarwala holds a B.S. in Biophysics from Stanford University, an M.D. from Harvard Medical School through the Harvard-MIT HST Program, and a Ph.D. in Biophysics from Harvard University, where her doctoral research conducted at the Broad Institute focused on genetic causes of human disease. She completed her residency in internal medicine at Stanford Hospital & Clinics.

Erez Chimovits, M.B.A, M.Sc., has served as a member of our board of directors since September 2025. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the board of directors of Upstream Bio Inc. (Nasdaq: UPB) since October 2021 and several private companies. Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.) from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd. from January 2001 to January 2007 and as Executive Vice President in Commercial Operations from December 1999 to January 2007. Mr. Chimovits holds an M.B.A., M.Sc. in Microbiology, and B.Sc. from Tel Aviv University.

David C. Lubner, has served as a member of our board of directors since June 2026. Mr. Lubner currently serves as a Venture Partner at RA Ventures since October 2025. Mr. Lubner is also the Co-Founder, President, Chief Operating Officer and member of the board of directors of Surmount LLC, an private early development life sciences company since August 2025. Previously, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., which was acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Prior to Ra Pharmaceuticals, he served as Chief Financial Officer of several biotech companies including Chief Financial Officer of PharMetrics Inc., a healthcare informatics company from September 1999 until it was acquired by IQVIA (formerly IMS Health) in 2005. Mr. Lubner has served on the board of directors of Crescent Biopharma (Nasdaq: CBIO) since April 2025 and Dyne Therapeutics (Nasdaq: DYN) since March 2020 and currently serves as a member of the board of directors at several private biotechnology companies. He previously served on the board of directors of Arcellx, Inc. (Nasdaq: ACLX) from August 2020 until its acquisition by Gilead Sciences, Inc. in April 2026, POINT Biopharma (Nasdaq: PNT) from June 2021 until its acquisition by Eli Lilly & Co. in December 2023, CARGO Therapeutics (Nasdaq: CRGX) from July 2023 to August 2025, Vor Biopharma (Nasdaq: VOR) from July 2020 to August 2025, Gemini Therapeutics (Nasdaq: GMTX) from April 2020 to December 2022, and Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a blank check company focused on the healthcare industry from May 2020 to June 2021. Mr. Lubner is a former Certified Public Accountant and received a B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.